$1.65
Value $297M
Century TherapeuticsvsMerck & Company
IPSC and MRK stock compared: price, dividend, valuation and results, from SEC filings.
+1.23%
$147.76
Value $365B
Century Therapeutics (IPSC) has a market value of $297M and Merck & Company (MRK) $365B. Over the last year, with dividends, IPSC moved +193.1% and MRK +66.3%. Dividend yield: IPSC none, MRK 2.30%.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
IPSC$297M
MRK$365B
MRK is 1,232 times IPSC
Revenue, 12 months
IPSC$109M
MRK$67.4B
MRK is 617 times IPSC
Net income, 12 months
IPSC-$99M
MRK$2.5B
Operating margin
IPSC-97.2%
MRK–
ROIC
IPSC-40.2%
MRK3.9%
44.1 points apart
P/E
IPSC–
MRK148.9
Dividend yield
IPSC0.0%
MRK2.3%
2.3 points apart
5-year return
IPSC-92.1%
MRK+104.9%
197.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
IPSC-92.1%
MRK+104.9%
| Period | IPSCWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +193.1%Price +193.1% | +66.3%Price +61.6% |
| 3 years since November 13, 2023 | +28.9%+8.8% a yearPrice +28.9% | +58.0%+16.5% a yearPrice +44.2% |
| 5 years since November 12, 2021 | -92.1%-39.8% a yearPrice -92.1% | +104.9%+15.4% a yearPrice +75.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
IPSCCentury TherapeuticsMRKMerck & Company
Valuation
IPSCMRK| Price | $1.65 | $147.76 |
|---|---|---|
| Market value | $297M | $365B |
| Enterprise value (EV) | $179M | $409B |
| P/E | – | 148.9 |
| P/E, 5-year median | – | 14.8 |
| P/B | 1.4 | 8.1 |
| EV/EBIT | – | 86.0 |
| Free cash flow yield | – | 4.0% |
Results and growth
IPSCMRK| Revenue, 12 months | $109M | $67.4B |
|---|---|---|
| Net income, 12 months | -$99M | $2.5B |
| Free cash flow, 12 months | -$85M | $14.7B |
| Earnings per share, 12 months | -$0.64 | $0.98 |
| Revenue growth, year on year | 1,556.8% | 1.3% |
| Revenue growth a year, past | +175.9%over 3 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
Margins and returns on capital
IPSCMRK| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | -97.2% | – |
| Net margin | -8.8% | 3.6% |
| ROIC | -40.2% | 3.9% |
| ROE | -47.4% | 5.2% |
Balance sheet
IPSCMRK| Cash | $117M | $9.7B |
|---|---|---|
| Total debt | $37M | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | – | 2.4× |
Dividends and buybacks
IPSCMRK| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Century Therapeutics or Merck & Company?
By market value, Merck & Company ($365B) is about 1,231.9 times Century Therapeutics ($297M), at today's prices.
How did IPSC and MRK stock do over the last 5 years?
Since November 12, 2021, IPSC's price moved -92.1% and MRK's +75.9%. With dividends: IPSC -92.1% (-39.8% a year), MRK +104.9% (+15.4% a year). Past returns do not predict future ones.
Which pays the higher dividend, IPSC or MRK?
The dividend yield at today's price is none for Century Therapeutics and 2.30% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
Which has the higher profit margins, Century Therapeutics or Merck & Company?
Over the last twelve months, the net margin was -8.8% for Century Therapeutics and 3.6% for Merck & Company, and the operating margin -97.2% and –. Revenue was $109M and $67.4B.
Which is the better investment, Century Therapeutics or Merck & Company?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.